Email: cspc@cspc.cn
Email: cspc@cspc.cn
October 28, 2022
The antibody-drug conjugate “SYS6002” (the “Product”) developed by CSPC has obtained clinical trial approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. A number of patent applications of the Product have been submitted in China and overseas.
SYS6002 is a monoclonal antibody-drug conjugate which can bind to specific receptors on the tumor surface and achieve tumor cell killing by entering the cells through endocytosis and releasing toxins. The indications for this clinical trial approval are advanced solid tumors. The Product has demonstrated good anti-tumor effects on a variety of cancers in the preclinical studies, providing a promising prospect of demonstrating good efficacy in subsequent clinical trials.
The Group will endeavor to push forward the clinical trials of the Product and strive to launch the Product as soon as possible.
